§
PatentCue
Patent Intelligence
Join Waitlist Sign In
← Back to Patent Explorer
US4014993A Expired / Lapsed US ⏱️ 0.0 years remaining

Inhibition of platelet aggregation with substituted phenylhydratropic acid compounds

Assignee: Pharmacia and Upjohn Co
•
Filing: 1975-11-17
•
Granted: 1977-03-29
•
Expires: 1995-11-17
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A process for inhibiting platelet aggregation by the addition of a member selected from the group consisting of a compound of the formula: ##STR1## WHEREIN IS PHENYL OR CYCLOHEXANE AND X and Y can be the same or different and are hydrogen, fluoro, chloro, bromo, alkyl of from 1 to 8 carbon atoms, inclusive or alkoxy of from 1 to 8 carbon atoms inclusive, and the pharmacologically acceptable salts thereof to in vivo and in vitro platelet systems. In vitro systems include whole blood as kept in blood banks, whole blood as used in heart-lung machines and platelet-rich concentrates. In vivo systems include human or animal bodies. The process provides a means for treating hemorrhage due to thrombocytopenia which in turn is caused by irradiation cancer chemotherapy or immunosuppressants as well as hemophilia due to cogenital defects.

Inventors

  • 👤 Neel C. Sekhar

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-02 18:43
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K35/00; A61K35/12; A61K35/14; A61K35/19

Claims Analysis

Total Claims: 8
Claim 1
Independent Claim 74 words
A process for inhibiting platelet aggregation in vitro comprising the addition of an effective amount of a compound of the formula: ##STR2## wherein is phenyl or cyclohexane and X and Y can be the same or different and are hydrogen, fluoro, chloro, bromo, alkyl of from 1 to 8 carbon atoms inclusive or alkoxy of from 1 to 8 carbon atoms, inclusive and the pharmacologically acceptable salts thereof to whole blood or platelet-rich concentrates.
Claim 2
Dependent Claim 74 words
A process for inhibiting platelet aggregation in vitro comprising the addition of an effective amount of a compound of the formula: ##STR2## wherein is phenyl or cyclohexane and X and Y can be the same or different and are hydrogen, fluoro, chloro, bromo, alkyl of from 1 to 8 carbon atoms inclusive or alkoxy of from 1 to 8 carbon atoms, inclusive and the pharmacologically acceptable salts thereof to whole blood or platelet-rich concentrates.
Claim 3
Dependent Claim 24 words
The process of claim 1 wherein the amount of the compound added is from about 0.01 to 50 micrograms per ml. of whole blood.
Claim 4
Dependent Claim 12 words
The process of claim 1 wherein the compound added is 3-fluoro-4-phenylhydratropic acid.
Claim 5
Dependent Claim 78 words
A process of prophylactic treatment to prevent clot formation comprising the administration of an effective amount of a compound of the formula: ##STR3## wherein is phenyl or cyclohexane and X and Y can be the same or different and are hydrogen, fluoro, chloro, bromo, alkyl of from 1 to 8 carbon atoms, inclusive or alkoxy of from 1 to 8 carbon atoms, inclusive, and the pharmacologically acceptable salts thereof to a human or animal having elevated platelet adhesiveness.
Claim 6
Dependent Claim 78 words
A process of prophylactic treatment to prevent clot formation comprising the administration of an effective amount of a compound of the formula: ##STR3## wherein is phenyl or cyclohexane and X and Y can be the same or different and are hydrogen, fluoro, chloro, bromo, alkyl of from 1 to 8 carbon atoms, inclusive or alkoxy of from 1 to 8 carbon atoms, inclusive, and the pharmacologically acceptable salts thereof to a human or animal having elevated platelet adhesiveness.
Claim 7
Dependent Claim 24 words
The process of claim 4 wherein the amount of the compound added is from about 0.01 to 50 micrograms per ml. of whole blood.
Claim 8
Dependent Claim 12 words
The process of claim 1 wherein the compound added is 3-fluoro-4-phenylhydratropic acid.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1980-03-28 1980-09-27 1981-03-29 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1984-03-28 1984-09-27 1985-03-29 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1988-03-28 1988-09-27 1989-03-29 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag